Disease Severity and Activity in Bronchiectasis: A Paradigm Shift in Bronchiectasis Management
- Author:
Yunjoo IM
1
;
James D. CHALMERS
;
Hayoung CHOI
Author Information
- Publication Type:Review
- From:Tuberculosis and Respiratory Diseases 2025;88(1):109-119
- CountryRepublic of Korea
- Language:English
- Abstract: Bronchiectasis has an increasing prevalence and substantial clinical and economic burden. Therefore, physicians should identify patients with bronchiectasis at high risk of disease progression to ensure optimal management in advance. The heterogeneity of bronchiectasis means it is unlikely that any single parameter could identify highrisk patients; therefore, disease severity is usually assessed using validated composite tools, such as the Bronchiectasis Severity Index, FACED, and Bronchiectasis Aetiology Comorbidity Index, to predict long-term outcomes in bronchiectasis. Disease severity, however, implies an advanced process with lung destruction. Earlier intervention may prevent disease progression and improve outcomes. To identify patients at risk, rather than patients with established advanced disease, we need to shift our focus from disease severity to disease activity. Disease activity denotes the activation level of underlying pathophysiological processes and can be measured using clinical presentations and biomarkers. This review discusses a paradigm shift in bronchiectasis management, focusing on disease activity rather than severity, to prevent disease progression.
